MarginsXMarginsX
Home › Markets › Health Care › IRLA

IRulya Therapeutics Inc. (IRLA)

IRLA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$37.36
-6.13% on the day
Market cap
$405.0M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerIRLA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2019
SEC CIK0001662774
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
29.7 months
$116.0M cash at June 30, 2026
Share count, 1 year
+3794.1%
2025-11-06 to 2026-11-05 · +4958.0% over 3 years
Going-concern doubt
No
10-Q filed November 13, 2026
Insider net buying, 12 months
-$174K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-13
Cash and burn$116.0M cash; operating cash flow -$11.7M a quarter.Report 2026-06-30
Shares outstanding10,841,470 (2026-11-05); 55,681,490 a year earlier; 42,868,947 three years earlier. 1y figure adjusted for splits (1-for-200 overall); 3y figure adjusted for splits (1-for-200 overall).Cover page 2026-11-05
Reverse splits, 3 years2; latest 1-for-20 on 2026-06-30Source 2026-06-30
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-07-31
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-09-04
AuditorBDO USA, P.C., San Jose, California, United StatesPCAOB Form AP 2026-04-16
Late filings, 12 months1 NT noticeNT 10-K 2026-04-01
Insider trades, 12 monthsBought $0, sold $174K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$75.5M-$18.9M$116.0M$0Needs four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed$35.9M-$7.6M$18.2M$0Needs four quarters10-Q 2026-05-11
Q4 2025
2025-12-31
Not filed-$39.5M-$10.5M$5.8M$0Needs four quarters10-K 2026-04-10
Q3 2025
2025-09-30
Not filed-$13.4M-$9.9M$6.5M$0Needs four quarters10-Q 2025-11-12
Q2 2025
2025-06-30
Not filed-$16.0M-$11.4M$16.8M$17.0MNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$15.0M-$9.6M$7.8M$15.3MNeeds four quarters10-Q 2026-05-11
Q4 2024
2024-12-31
Not filed-$12.5M-$7.6M$6.2M$14.3MNeeds four quarters10-K 2026-04-10
Q3 2024
2024-09-30
Not filed-$5.5M-$7.3M$2.7M$14.9MNeeds four quarters10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-07-31
Latest annual report10-K2026-04-10
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-10-02

Source: SEC EDGAR submissions feed, 473 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+28.4%
1 month+42.8%
3 months+22.8%
Year to date-94.1%
1 year-88.2%
From 52-week high-95.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
SLBTSL Science Holding Limited$0.7195-3.42%$403.5M
TECXTectonic Therapeutic Inc.$20.98-0.76%$418.5M
TVGNTevogen Inc.$6.22+3.67%$422.2M
ALECAlector Inc.$2.57+1.18%$382.6M
FENCFennec Pharmaceuticals Inc.$12.76+9.81%$450.5M
CADLCandel Therapeutics Inc.$5.81-6.29%$455.8M
CCCCC4 Therapeutics Inc.$2.65-3.99%$348.0M
RGNXREGENXBIO Inc.$7.32-4.19%$484.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier